Retatrutide (Reta): Triple Incretin Research Guide

Retatrutide — colloquially known as Reta — is a once-weekly triple incretin receptor agonist developed by Eli Lilly that simultaneously activates GLP-1R, GIPR, and the glucagon receptor (GcgR), making it the first published compound to achieve pharmacological tri-agonism across all three primary incretin and counterregulatory hormone receptors. Where semaglutide (Ozempic) targets one receptor and tirzepatide (Mounjaro) targets two, retatrutide (Reta) targets three — adding glucagon receptor co-agonism that theoretically increases hepatic energy expenditure via a mechanism absent from both prior generations of GLP-1-based compounds.

This article covers the molecular mechanism of retatrutide (Reta), its pharmacological profile relative to semaglutide and tirzepatide, the Phase II trial data published in 2023, and its current Phase III TRIUMPH programme status. Prescription-only medication in many jurisdictions. For research purposes only. Not for human consumption.

What Is Retatrutide (Reta)?

Retatrutide (also known colloquially as Reta) is a once-weekly injectable peptide developed by Eli Lilly as the successor compound to tirzepatide (Mounjaro). It is classified as a GIP/GLP-1/glucagon receptor tri-agonist — activating three distinct GPCRs simultaneously: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GcgR).

The addition of glucagon receptor agonism to the dual GLP-1/GIP profile of tirzepatide is the pharmacological innovation that defines retatrutide's research profile. Glucagon is historically known as a counter-regulatory hormone — its primary endogenous role is hepatic glucose production in hypoglycaemic states. However, glucagon receptor activation also stimulates hepatic fatty acid oxidation and thermogenesis, effects that have attracted significant research interest as potential contributors to a more complete metabolic research profile.

Molecular Profile

Retatrutide Mechanism: The Three Receptor Targets

GLP-1 Receptor Agonism

Retatrutide's GLP-1R activation produces the same downstream effects characterised in semaglutide research: glucose-dependent insulin secretion from pancreatic beta cells, glucagon suppression from alpha cells, gastric emptying delay, and satiety signalling via hypothalamic GLP-1R expression. This arm of the mechanism is the most extensively characterised of the three, with over a decade of published semaglutide data providing the mechanistic reference base.

GIP Receptor Agonism

The GIP (glucose-dependent insulinotropic polypeptide) receptor component of retatrutide is shared with tirzepatide (Mounjaro). GIP receptor activation amplifies the insulin secretion response to glucose and appears to modulate adipocyte biology directly via adipose tissue GIPR expression. Published tirzepatide data — including SURMOUNT and SURPASS trial series — provides the reference base for the GIP/GLP-1 dual axis component of retatrutide's mechanism.

Glucagon Receptor Agonism — The Novel Addition

The GcgR component is what separates retatrutide (Reta) from all prior incretin compounds. Glucagon receptor activation in hepatocytes stimulates glycogenolysis, gluconeogenesis, and — crucially — fatty acid beta-oxidation. The theoretical model is that GcgR-mediated hepatic energy expenditure adds an energy output dimension to the GLP-1/GIP energy intake reduction effects — which means the triple agonist addresses both sides of the energy balance equation simultaneously in a way that neither semaglutide nor tirzepatide can.

The risk of adding GcgR agonism is glycaemia — glucagon raises blood glucose. Retatrutide's design balances this by calibrating the GcgR agonism at a potency level intended to produce hepatic energy expenditure effects without overriding the insulin-stimulating effects of its GLP-1R and GIPR components. The Phase II TRIUMPH data assessed this balance in 338 participants over 48 weeks.

Three Generations of Incretin Pharmacology

TRIUMPH Phase II Trial: Published Evidence

The Phase II TRIUMPH trial results for retatrutide (Reta) were published by Jastreboff AM et al. in the New England Journal of Medicine in June 2023 (PMID: 37385430). The trial enrolled 338 adults across five dose cohorts (placebo, 1mg, 4mg, 8mg, and 12mg weekly) over 48 weeks, with a 28-week safety follow-up period.

The primary published finding was dose-dependent change in body weight from baseline across the 48-week treatment period, with gastrointestinal adverse events (nausea, vomiting, diarrhoea) the most commonly reported safety findings — consistent with the GLP-1R agonism component's established tolerability profile from semaglutide and tirzepatide literature. The trial design was specifically structured to characterise the dose-response relationship across five levels, providing the pharmacological data necessary to select Phase III doses.

Phase III TRIUMPH Programme: Current Status

Following the Phase II data, Eli Lilly initiated the Phase III TRIUMPH programme for retatrutide (Reta) in 2023-2024. The Phase III programme comprises multiple trials across metabolic, cardiovascular, and hepatic research contexts, designed to generate the regulatory-standard evidence package required for potential approval. Primary completion dates for the Phase III trials are anticipated in 2025-2026, with regulatory submissions contingent on outcomes.

Retatrutide (Reta) is not currently approved by the MHRA or any major regulatory body for any therapeutic indication. It is in active Phase III clinical development. Pure Grade Labs supplies retatrutide strictly as a research chemical for laboratory use, not as a therapeutic agent.

Frequently Asked Questions

Summary

Retatrutide (Reta) (CAS: 2381089-83-2) is the most pharmacologically complex incretin compound currently in clinical development, adding GcgR agonism to the GLP-1R/GIPR dual profile of tirzepatide (Mounjaro) to create a theoretically more comprehensive metabolic research profile. The Phase II TRIUMPH trial published in the NEJM in 2023 provides the current human evidence base; Phase III data is pending.

For researchers studying the incretin receptor system, retatrutide (Reta) represents the current frontier of published triple-receptor pharmacology. Available alongside semaglutide and tirzepatide from Pure Grade Labs at research grade with batch-specific COA. Prescription-only medication — for laboratory research only. Not for human consumption.

References

1. Jastreboff AM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Metabolic Syndrome. New England Journal of Medicine. PMID: 37385430. DOI: 10.1056/NEJMoa2301972.
2. Drucker DJ. (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism. PMID: 34902573. DOI: 10.1016/j.molmet.2021.101351.
3. Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. PMID: 33567185.
4. Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. PMID: 35658024. DOI: 10.1056/NEJMoa2206038.